2023
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
McHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.Peer-Reviewed Original ResearchConceptsOvarian serous borderline tumorsSerous borderline tumorsNon-invasive implantsDisease-free survivalKRAS mutationsTumor recurrenceExtraovarian implantsAdverse disease-free survivalWorse disease-free survivalHigher stage diseaseKRAS mutation testingHigher tumor stageWild-type KRASBRAF V600E mutationBRAF mutational analysisBorderline tumorsClinical outcomesHistological subtypesTumor stageBRAF mutationsUseful biomarkerInvasive implantsTumors correlatesV600E mutationMutational status
2020
Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease
Zheng XZ, Qin XY, Chen SW, Wang P, Zhan Y, Zhong PP, Buza N, Jin YL, Wu BQ, Hui P. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. Modern Pathology 2020, 33: 1979-1988. PMID: 32404958, DOI: 10.1038/s41379-020-0566-4.Peer-Reviewed Original ResearchConceptsNon-molar gestationsGestational trophoblastic diseaseTrophoblastic diseaseHigh riskGestational trophoblastic neoplasiaProducts of conceptionPatient demographicsClinical followClinical outcomesGynecology HospitalTrophoblastic neoplasiaBeijing ObstetricsFIGO criteriaChinese patientsClinical prognosisPatient managementLarge cohortGestationMolar gestationDiseaseGenetic abnormalitiesChromosomal monosomyChromosomal aneuploidyHydatidiformUniparental disomy
2018
Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions
Liu Y, Blakely M, Sigel K, Thin TH, Hui P, Donovan M, Gaisa MM. Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions. AIDS 2018, 32: 2309-2316. PMID: 30005024, PMCID: PMC6862769, DOI: 10.1097/qad.0000000000001957.Peer-Reviewed Original ResearchConceptsLow-grade squamous intraepithelial lesionsAnal low-grade squamous intraepithelial lesionsSquamous intraepithelial lesionsHigh-grade squamous intraepithelial lesionsBiomarker p16Intraepithelial lesionsIndex lesionP16 immunohistochemistryProgression riskHigh-risk human papillomavirus DNACD4 T-cell countFormer smoker statusHistory of condylomaT-cell countsHR-HPV DNAYear of diagnosisHuman papillomavirus DNASemi-quantitative scoring systemAssociation of predictorsLogistic regression modelsOnly significant predictorOrdinal logistic regression modelsClinical outcomesUnderwent surveillanceRetrospective study
2017
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome
Zuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Modern Pathology 2017, 31: 350-357. PMID: 29027536, DOI: 10.1038/modpathol.2017.121.Peer-Reviewed Original ResearchConceptsAtypical proliferative serous tumorNon-invasive implantsDisease-specific survivalSerous borderline tumorsHigh recurrence rateWorse disease-specific survivalStage IIIC diseaseKRAS mutationsInvasive implantsBRAF V600E mutationBorderline tumorsSerous tumorsRecurrence rateIIIC diseaseClinical outcomesHistological subtypesPrognostic indicatorExtraovarian implantsV600E mutationLow-grade serous carcinomaUnfavorable disease-specific survivalAdverse clinical outcomesHigher stage diseaseSignificant prognostic indicatorBRAF mutation frequencyPathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerPediatric papillary thyroid cancerPrognostic implicationsPediatric papillary thyroid carcinomaNegative casesBRAF-negative casesBRAF-negative patientsBRAF-positive casesTertiary medical centerAggressive clinical coursePapillary thyroid carcinomaSurgical pathology diagnosisCommon genetic aberrationsNegative patientsAggressive courseClinical coursePathologic characteristicsCase seriesClinical outcomesRetrospective reviewAggressive featuresPediatric casesRecurrence rateRetrospective studySingle institution
2005
Minimal uterine serous carcinoma: a clinicopathological study of 40 cases
Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Modern Pathology 2005, 18: 75-82. PMID: 15389257, DOI: 10.1038/modpathol.3800271.Peer-Reviewed Original ResearchConceptsMinimal uterine serous carcinomaUterine serous carcinomaSerous carcinomaEndometrial polypsExtrauterine tumorsInvasive serous carcinomasSurgical staging procedureHigh nuclear gradeSurgical stagingClinicopathological studyOverall survivalStaging procedureClinical outcomesClinicopathologic featuresStromal invasionImmunohistochemical profileNuclear gradeMutant p53 proteinCarcinomaPatientsPolypsTumorsP53 proteinLesionsInvasion